Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, et al. Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression. Clin Cancer Res 2023 Jun 16:CCR-23-0797. doi: 10.1158/1078-0432.CCR-23-0797.
PMID: 37327320